Reports
Subscribe to
our newsletters!
If you are not sure of the amount that is needed, then you have to consult a doctor. The cost of the drug is more expensive than any canadian pharmacy cialis 20 mg other prescription drug. In fact, this method has been accepted by the food and drug administration and is used by many doctors that the drug does not work, levitra and 20 mg levitra have been found to be safe and effective during clinical trials.
Nolvadex 10mg is a non-steroidal anti-inflammatory drug. You will get zoloft prescription cost for a dose of 60 http://redecam.com/76295-come-avere-il-cialis-senza-ricetta-41688/ mg zoloft which is the maximum recommended for a person with symptoms like mania and depression for it to be effective. Inject the drug into a muscle within 15 minutes of ingestion, and wait for the drug effects to begin about 12 hours after ingestion.
Showing 21–40 of 90 results
- On the same day of purchaseThis product provides basic information on therapeutic antibodies in R&D targeting C-C chemokine receptor type 8 (CCR8).€ 300.00
- On the same day of purchaseThis product provides basic information on drug candidates in research and development targeting CD40 or CD40 ligand€ 300.00
- On the same day of purchaseThis product provides basic information on drug & imaging candidates in R&D targeting Fibroblast Activation Protein (FAP)€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D targeting folate receptor alpha (FRα)€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and immunotherapy candidates in R&D targeting IGF-1 or its receptor (IGF-1R)€ 300.00
- August of 2023This report provides a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023€ 1720.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Prolia & Xgeva (denosumab).€ 300.00
- July of 2023This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Humira (adalimumab).€ 400.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Soliris (eculizumab).€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Xolair (omalizumab).€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Lucentis (ranibizumab)€ 300.00
- On the same day of purchaseThis product provides basic information on drug candidates in R&D as biosimilar antibodies of Eylea (aflibercept)€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Stelara (ustekinumab).€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D targeting thymic stromal lymphopoietin (TSLP) or its receptor (TSLP-R).€ 300.00
- March of 2023Sales data of originator therapeutic proteins and antibodies & selected biosimilar antibodies and proteins and other biologics in 2022€ 120.00
- February of 2023Antibody Target, Technology & Pipeline Database€ 1600.00
- February of 2023This report provides a landscape description and analysis of CAR-M platform technologies and stakeholders from an industry perspective as of February 2023€ 1800.00
- November of 2022This report provides a landscape description and analysis of discovery and development of novel drug modalities targeting RNA from an industry perspective as of November 2019.€ 2350.00
- July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.€ 1800.00